Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism
Joep Titulaer, O. Radhe, Klara Danielsson, et al.
European Neuropsychopharmacology (2022) Vol. 62, pp. 22-35
Open Access | Times Cited: 20

Showing 20 citing articles:

The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses
Roger S. McIntyre, Suresh Durgam, S.G. Kozauer, et al.
European Neuropsychopharmacology (2023) Vol. 68, pp. 78-88
Open Access | Times Cited: 36
New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
Aineng Peng, Chai Jian-bo, Haiyuan Wu, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 607-620
Open Access | Times Cited: 10
Adjunctive lumateperone ( ITI ‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial
Trisha Suppes, Suresh Durgam, S.G. Kozauer, et al.
Bipolar Disorders (2023) Vol. 25, Iss. 6, pp. 478-488
Open Access | Times Cited: 11
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective
Veronica Begni, Alessia Marchesin, Marco Andrea Riva
Pharmacological Research (2025), pp. 107690-107690
Open Access
The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review
Giulio Longo, Angelica Cicolini, Laura Orsolini, et al.
Brain Sciences (2023) Vol. 13, Iss. 12, pp. 1641-1641
Open Access | Times Cited: 10
Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022
Pengfei Xu, Lijun Zhu, Desheng Zhang, et al.
Results in Chemistry (2024) Vol. 7, pp. 101446-101446
Open Access | Times Cited: 3
Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways
Ting Zhang, Chang Liu, Ning Zhong, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10668-10668
Open Access | Times Cited: 3
Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation
Sophie Dutheil, Luke S. Watson, Robert E. Davis, et al.
Journal of Neuroscience (2022) Vol. 43, Iss. 5, pp. 863-877
Open Access | Times Cited: 13
Canonical and Non-Canonical Antipsychotics’ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia
Andrea de Bartolomeis, Mariateresa Ciccarelli, Giuseppe De Simone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5945-5945
Open Access | Times Cited: 7
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data
Konstantinos Ν. Fountoulakis, Mauricio Tohen, Carlos A. Zarate
European Neuropsychopharmacology (2024) Vol. 81, pp. 1-9
Closed Access | Times Cited: 2
Graphene quantum dots as eco-friendly fluorescent probes for sensitive and selective determination of lumateperone in pharmaceutical preparation: Greenness and blueness assessment
Arwa Sultan Alqahtani, Farooq M. Almutairi, Muneef M. Aldhafeeri, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2024) Vol. 327, pp. 125342-125342
Closed Access | Times Cited: 2
Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences
Gloria Munayco Maldonado, Thomas L. Schwartz
International Clinical Psychopharmacology (2023) Vol. 39, Iss. 1, pp. 4-16
Closed Access | Times Cited: 6
Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study
Ginevra Lombardozzi, Giada Trovini, Emanuela Amici, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 6
Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults
Hagar Abuelazm, Omar H. Elsayed, Rif S. El‐Mallakh
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 8, pp. 751-756
Closed Access | Times Cited: 4
Overview of approved psychiatric medications 2008-2023: A systematic review
Waguih William IsHak, Jayant Totlani, Nathalie Murphy, et al.
World Journal of Advanced Research and Reviews (2024) Vol. 21, Iss. 3, pp. 885-915
Open Access | Times Cited: 1
Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system
Shengzhu Sun, Ying Zhang, Hong-Yun Wu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access
New antipsychotic medication
Krzysztof Wojtasik-Bakalarz, Marcin Siwek
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 19-38
Open Access | Times Cited: 1
Lumateperone in the treatment of psychiatric disorders – a review of the literature
Ada Kaczmarek, Wiktor Szymajda, Katarzyna Dettlaff
Pharmacotherapy in Psychiatry and Neurology (2023) Vol. 39, Iss. 1, pp. 39-52
Open Access
Crystal structure and X-ray powder diffraction data for Lumateperone tosylate
Jiyong Liu, Dier Shi, Shuna Liu, et al.
Powder Diffraction (2023), pp. 1-5
Closed Access
Page 1

Scroll to top